Catalyst Database

KOMET-001 trial. 8/3/23- Updated data from Ph1 at EHA 2023. 5/14/24 Enrolls 85 patients, completion by mid-2024. 2/6/25- Topline data announced. 2/26/25- NDA submission in Q2 2025.

Initial data at SITC 2022. 02/27/24- Enrollment ongoing. Data update in H1 2025.

Hypothalamic obesity trial. 1/4/24- Completed enrollment. Q2 '24- Dosed first patient in 12-patient Japanese cohort Ph3 trial w/ topline data in H1 2025. Presents at ENDO '24. 11/18/24- 34-wk substudy in congenital patients aged 4 yrs and older to begin enrollment in Q1 2025.

3/25/24- First patient dosed. Preclinical data at ENDO'24. 5/7/24- Data in H1 2025. 2/26/25- Part C to begin enrolling patients Q2 2025.

NAVAL-1 DLBCL study. 11/13/24- Stage 1 data in H1 2025.

NAVAL-1 study. 11/13/24- Prelim data from expansion phase in H1 2025 and interim analysis outcome in 2026. File NDA for accelerated approval based on the interim analysis in 2026.

Suspected Big Mover: HERIZON-GEA-01 trial. 2/25/25- Topline PFS data in H2 2025.

MARCH study. 11/13/23- New data presentation at AASLD 2023. 10/31/24- Present Part B portion at AASLD '24 on November 2024 w/ further data in Q2 2025. 11/15/24- Positive End-of-Treatment results presented at AASLD The Liver Meeting. 24-wk follow-up data expected in Q2 2025 .

LUNAR-OTC. 8/7/23- Completed enrollment & dosing of all cohorts in Ph1b SAD study in U.S. 7/1/24- To expand program in US. 3/6/25- Interim data in Q2 2025.

STARBORN-1 trial. 10/23- Trial initiated. 5/2/24- Dosing continues to progress. 9/9/24 Complete first cohort. Initial results in H1 2025. 3/5/25- Interim update by the end of H1 2025.